These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32097671)

  • 21. Immune-related adverse events of checkpoint inhibitors.
    Ramos-Casals M; Brahmer JR; Callahan MK; Flores-Chávez A; Keegan N; Khamashta MA; Lambotte O; Mariette X; Prat A; Suárez-Almazor ME
    Nat Rev Dis Primers; 2020 May; 6(1):38. PubMed ID: 32382051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune mechanisms of toxicity from checkpoint inhibitors.
    Wang SJ; Dougan SK; Dougan M
    Trends Cancer; 2023 Jul; 9(7):543-553. PubMed ID: 37117135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
    Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
    Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
    Gomes N; Sibaud V; Azevedo F; Magina S
    Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
    Joshi M; Ansell SM
    J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-related adverse events of checkpoint inhibitors.
    Nat Rev Dis Primers; 2020 May; 6(1):39. PubMed ID: 32382085
    [No Abstract]   [Full Text] [Related]  

  • 30. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
    Cortellini A; Buti S; Agostinelli V; Bersanelli M
    Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    König D; Läubli H
    Pharmacology; 2021; 106(3-4):123-136. PubMed ID: 32721966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
    Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
    Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
    Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of immune checkpoint inhibitor-related adverse events: A review of case reports.
    Si X; Song P; Ni J; Di M; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Yang X; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):498-504. PubMed ID: 31970923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
    Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
    Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
    Dermime S; Merhi M; Merghoub T
    Front Immunol; 2021; 12():781872. PubMed ID: 34745152
    [No Abstract]   [Full Text] [Related]  

  • 40. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.